CLINICAL TRIALS PROFILE FOR ENSIFENTRINE
✉ Email this page to a colleague
Clinical Trials for Ensifentrine
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT03937479 ↗ | Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | Completed | IQVIA | Phase 2 | The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium over 4 weeks of treatment. This study is intended to support optimal dose selection for a Phase III program evaluating RPL554 as an add-on treatment to standard of care therapy. |
NCT03937479 ↗ | Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | Completed | Iqvia Pty Ltd | Phase 2 | The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium over 4 weeks of treatment. This study is intended to support optimal dose selection for a Phase III program evaluating RPL554 as an add-on treatment to standard of care therapy. |
NCT03937479 ↗ | Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | Completed | LGC Limited | Phase 2 | The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium over 4 weeks of treatment. This study is intended to support optimal dose selection for a Phase III program evaluating RPL554 as an add-on treatment to standard of care therapy. |
NCT03937479 ↗ | Study Investigating the Effect of 4 Doses of RPL554 Given in Addition to Tiotropium to Patients With COPD | Completed | Verona Pharma plc | Phase 2 | The purpose of this study is to investigate the dose response of RPL554 in patients with moderate to severe CHRONIC OBSTRUCTIVE PULMONARY DISEASE that are still symptomatic despite treatment with a stable background of tiotropium over 4 weeks of treatment. This study is intended to support optimal dose selection for a Phase III program evaluating RPL554 as an add-on treatment to standard of care therapy. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Ensifentrine
Condition Name
Clinical Trial Locations for Ensifentrine
Trials by Country
Clinical Trial Progress for Ensifentrine
Clinical Trial Phase
Clinical Trial Sponsors for Ensifentrine
Sponsor Name